Cargando…
Public economic gains from tax-financed investments in childhood immunization in the United States
The emergence of COVID-19 has displayed the importance of immunization and the need for continued public investment in vaccination programs. Globally, national vaccination programs rely heavily on tax-financed expenditure, requiring upfront investments and ongoing financial commitments. To evaluate...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584131/ https://www.ncbi.nlm.nih.gov/pubmed/37851624 http://dx.doi.org/10.1371/journal.pgph.0002461 |
_version_ | 1785122686977966080 |
---|---|
author | Connolly, Mark P. Kotsopoulos, Nikolaos Roberts, Craig Kotlikoff, Laurence Bloom, David E. Hu, Tianyan Nyaku, Mawuli |
author_facet | Connolly, Mark P. Kotsopoulos, Nikolaos Roberts, Craig Kotlikoff, Laurence Bloom, David E. Hu, Tianyan Nyaku, Mawuli |
author_sort | Connolly, Mark P. |
collection | PubMed |
description | The emergence of COVID-19 has displayed the importance of immunization and the need for continued public investment in vaccination programs. Globally, national vaccination programs rely heavily on tax-financed expenditure, requiring upfront investments and ongoing financial commitments. To evaluate annual public investments, we conducted a fiscal analysis that quantifies the public economic consequences to government in the United States attributable to childhood vaccination. To estimate the change in net government revenue, we developed a decision-analytic model that quantifies lifetime tax revenues and transfers based on changes in morbidity and mortality arising from vaccination of the 2017 U.S. birth cohort. Reductions in deaths and comorbid conditions attributed to pediatric vaccines were used to derive gross lifetime earnings gains, tax revenue gains attributed to averted morbidity and mortality avoided, disability transfer cost savings, and averted special education costs associated with each vaccine. Our analysis indicates a fiscal dividend of $41.7 billion from vaccinating this cohort. The bulk of this gain for government reflects avoiding the loss of $30.6 billion in present-value tax revenues. All pediatric vaccines raise tax revenues by reducing vaccine-preventable morbidity and mortality in amounts ranging from $7.3 million (hepatitis A) to $20.3 billion (diphtheria) over the life course. Based on public investments in pediatric vaccines, a benefit-cost ratio of 17.8 was calculated for each dollar invested in childhood immunization. The public economic yield attributed to childhood vaccination in the U.S. is significant from a government perspective, providing fiscal justification for ongoing investment. |
format | Online Article Text |
id | pubmed-10584131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-105841312023-10-19 Public economic gains from tax-financed investments in childhood immunization in the United States Connolly, Mark P. Kotsopoulos, Nikolaos Roberts, Craig Kotlikoff, Laurence Bloom, David E. Hu, Tianyan Nyaku, Mawuli PLOS Glob Public Health Research Article The emergence of COVID-19 has displayed the importance of immunization and the need for continued public investment in vaccination programs. Globally, national vaccination programs rely heavily on tax-financed expenditure, requiring upfront investments and ongoing financial commitments. To evaluate annual public investments, we conducted a fiscal analysis that quantifies the public economic consequences to government in the United States attributable to childhood vaccination. To estimate the change in net government revenue, we developed a decision-analytic model that quantifies lifetime tax revenues and transfers based on changes in morbidity and mortality arising from vaccination of the 2017 U.S. birth cohort. Reductions in deaths and comorbid conditions attributed to pediatric vaccines were used to derive gross lifetime earnings gains, tax revenue gains attributed to averted morbidity and mortality avoided, disability transfer cost savings, and averted special education costs associated with each vaccine. Our analysis indicates a fiscal dividend of $41.7 billion from vaccinating this cohort. The bulk of this gain for government reflects avoiding the loss of $30.6 billion in present-value tax revenues. All pediatric vaccines raise tax revenues by reducing vaccine-preventable morbidity and mortality in amounts ranging from $7.3 million (hepatitis A) to $20.3 billion (diphtheria) over the life course. Based on public investments in pediatric vaccines, a benefit-cost ratio of 17.8 was calculated for each dollar invested in childhood immunization. The public economic yield attributed to childhood vaccination in the U.S. is significant from a government perspective, providing fiscal justification for ongoing investment. Public Library of Science 2023-10-18 /pmc/articles/PMC10584131/ /pubmed/37851624 http://dx.doi.org/10.1371/journal.pgph.0002461 Text en © 2023 Connolly et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Connolly, Mark P. Kotsopoulos, Nikolaos Roberts, Craig Kotlikoff, Laurence Bloom, David E. Hu, Tianyan Nyaku, Mawuli Public economic gains from tax-financed investments in childhood immunization in the United States |
title | Public economic gains from tax-financed investments in childhood immunization in the United States |
title_full | Public economic gains from tax-financed investments in childhood immunization in the United States |
title_fullStr | Public economic gains from tax-financed investments in childhood immunization in the United States |
title_full_unstemmed | Public economic gains from tax-financed investments in childhood immunization in the United States |
title_short | Public economic gains from tax-financed investments in childhood immunization in the United States |
title_sort | public economic gains from tax-financed investments in childhood immunization in the united states |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584131/ https://www.ncbi.nlm.nih.gov/pubmed/37851624 http://dx.doi.org/10.1371/journal.pgph.0002461 |
work_keys_str_mv | AT connollymarkp publiceconomicgainsfromtaxfinancedinvestmentsinchildhoodimmunizationintheunitedstates AT kotsopoulosnikolaos publiceconomicgainsfromtaxfinancedinvestmentsinchildhoodimmunizationintheunitedstates AT robertscraig publiceconomicgainsfromtaxfinancedinvestmentsinchildhoodimmunizationintheunitedstates AT kotlikofflaurence publiceconomicgainsfromtaxfinancedinvestmentsinchildhoodimmunizationintheunitedstates AT bloomdavide publiceconomicgainsfromtaxfinancedinvestmentsinchildhoodimmunizationintheunitedstates AT hutianyan publiceconomicgainsfromtaxfinancedinvestmentsinchildhoodimmunizationintheunitedstates AT nyakumawuli publiceconomicgainsfromtaxfinancedinvestmentsinchildhoodimmunizationintheunitedstates |